Long-Term Safety Considerations As a relatively new class of medications, the long-term safety profile of GLP-1 agonists is still under evaluation
GLP-1 receptor agonists aid in maintaining balanced blood sugar levels
Similarly, tirzepatide (Zepbound) demonstrated up to 22.5% weight loss in a 72-week trial with the same approach
It increases dopamine and norepinephrine to help with focus, attention, impulse control, and reducing hyperactivity
Food and Drug Administration has recorded 209 incidents of Wegovy patients suffering from gastrointestinal disorders this year, 42 of whom were hospitalized
Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.710.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.530.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.921.03) and proliferative DR (OR=0.98, 95% CI, 0.911.05)